What We Treat

The Aflac Cancer Center offers a large team of providers with specialized expertise in treating all forms of childhood leukemia and lymphoma. Each year, our program cares for approximately 125 newly diagnosed patients using a variety of treatment protocols, including blood and marrow transplantation and Phase I and Phase II trials of novel agents for children whose cancer has relapsed or is not responding to treatment.

What is leukemia?

Leukemia is a cancer of the white blood cells. When a child has leukemia, his bone marrow produces a large number of abnormal white blood cells. These abnormal white blood cells cannot protect against disease. They also interfere with the child’s production of red blood cells and platelets, which can cause anemia and bleeding problems.

What is lymphoma?

Lymphoma is a cancer that starts in a child’s lymphatic tissues, including lymph nodes, thymus, spleen, tonsils, adenoids and bone marrow. Lymphoma is the third most common type of cancer in children.

At the Aflac Cancer and Blood Disorders Center, our large team of providers offers specialized expertise in treating all forms of leukemia and lymphoma, including:

  • Acute lymphoblastic leukemia (ALL)
  • Acute myeloid leukemia (AML)
  • Hodgkin lymphoma
  • Non-Hodgkin lymphoma (NHL)

Our Unique Approach

We are home to one of the the largest pediatric cancer programs in the country, which follows more than 780 children and young adults with leukemia and lymphoma each year.  Combining the latest proven technology and research with a caring, child-friendly approach, makes the Aflac Cancer and Blood Disorders Center a top choice for the treatment of childhood leukemia and lymphoma.

Our highlights

  • U.S. News & World Report ranks us among the top pediatric cancer programs in the country.
  • We have doctors and scientists with national and international leadership roles in the diagnosis and treatment of ALL, AML and Hodgkin lymphoma.
  • Our interactive translational research program works to apply new knowledge and advances in the fight against cancer.
  • We are members of the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) and COG Phase I consortia.
  • We are one of a select group of centers offering chimeric antigen receptor (CAR) T cell therapy for relapsed leukemia.

Innovative research

Our team is committed to advancing research and medicine by developing new techniques, treatment and cures for children and young adults with leukemia and lymphoma. We are home to one of the largest clinical trial programs in the country—offering our patients access to some of the most novel treatment options in the country.

Learn more about our research efforts


Helpful Resources

New patient forms

Request a new patient appointment

Before your visit

Learn how to prepare for your visit to the Aflac Cancer Center, including information about our transitional housing options for families traveling from outside of Atlanta.

Get information and tips

Camps, events and support groups

Camps, retreats and other events offer many therapeutic benefits for children and families who are dealing with serious illness.

Camps, events and support groups

Second opinions and international services

We understand you want to be certain your child is receiving the best possible treatment available anywhere in the world. Second opinions can help provide the information you need to make an informed decision about the treatment for your child. For families traveling outside the U.S., we are here to help meet your unique needs and challenges.

Learn more about our second opinion services

Learn more about our international services

Donate

Learn how you can help make a difference in the life of a child battling cancer or a blood disorder.

Join the fight against childhood cancer and blood disorders

Learn more about how Aflac supports us

Meet the Team

Highlighted Research

Lubing Gu, Ph.D., and Muxiang Zhou, M.D., recently had their leukemia research highlighted in Cancer Cell. Doctors Gu and Zhou have developed novel inhibitors to block the interaction between the mouse double minute 2 homolog (MDM2) protein and X-linked inhibitor of apoptosis protein (XIAP), two critical proteins in cancer progression.

Meet our leukemia and lymphoma team

Led by Sharon Castellino, MD, Director of Leukemia and Lymphoma, our team includes the following pediatric oncologists: